Johnson & Johnson, ViaCyte, and the quest for a diabetes cure

05 Feb 2016


Following successful results in animal studies, Johnson & Johnson has joined forces with biotech company ViaCyte to speed development of the first stem cell treatment for Type I Diabetes.

Fox News


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story